What is the Type 1 Diabetes?

 

What is the Type 1 Diabetes?

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth. Importantly, insulin allows glucose to enter muscle and adipose cells, stimulates the liver to store glucose as glycogen and synthesize fatty acids, stimulates the uptake of amino acids, inhibits the breakdown of fat in adipose tissue, and stimulates the uptake of potassium into cells. Individuals with type 1 diabetes mellitus require life-long insulin replacement therapy. Without insulin, diabetic ketoacidosis (DKA) develops and is life-threatening.

Who are the leading Type 1 Diabetes Market Companies?

Some of the key players of the Type 1 Diabetes Market includes Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and others.

What is the Type 1 Diabetes Emerging Drugs?

·         Teplizumab: Prevention Bio

Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events.

·         Emricasan: Histogen

Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.

·         VX-880: Vertex Pharmaceuticals

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection.

Some of the key facts of the Type 1 Diabetes Market Report

·         According to the National Diabetes Statistics Report (2020), 34.2 million people in the United States have diabetes in 2018, accounting for 10.5% of the total population.

·         According to a Secondary search Type 2 Diabetes is more prevalent than Type 1 diabetes.

·         Type 1 diabetes may affect anybody at any age, although it impacts children and adolescents the most commonly. Over one million children and adolescents under the age of 20 have type 1 diabetes, according to the International Diabetes Federation (IDF).

What is the Type 1 Diabetes Market Outlook?

The Type 1 Diabetes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Type 1 Diabetes market trends by analyzing the impact of current Type 1 Diabetes therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of Type 1 Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Type 1 Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

What is the Type 1 Diabetes Market Size?

Type 1 Diabetes market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Type 1 Diabetes in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period. The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Type 1 Diabetes market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Type 1 Diabetes market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

What is the Type 1 Diabetes Market Insights?

People with type 1 diabetes need to follow a different type of plan. A treatment plan, also called a diabetes management plan, helps people to manage their diabetes and stay healthy and active. Everyone’s plan is different, and is based upon a person’s health needs and the suggestions of the diabetes health care team. The goal of the treatment is to keep your blood sugar level as close to normal as possible to delay or prevent complications. Generally, the goal is to keep the daytime blood sugar levels before meals between 80 and 130 mg/dL (4.44 to 7.2 mmol/L) and the after-meal numbers no higher than 180 mg/dL (10 mmol/L) two hours after eating. 

What is the Type 1 Diabetes Treatment Market?

Type 1 diabetes arises in response to the complete inability of the pancreas to produce this essential hormone, you need to provide your body with supplemental insulin. Having enough insulin is critical because this hormone is responsible for helping to regulate your blood sugar and keep it in a healthy range—not too high (hyperglycemia) and not too low (hypoglycemia). It is advised to take insulin several times a day, including the time before and after the meal. Several types of insulin are available. Each type starts to work at a different speed, known as “onset,” and its effects last a different length of time, known as “duration.” Most types of insulin reach a peak, which is when they have the strongest effect.

What are the Type 1 Diabetes Market Drivers?

·         Rise in Insulin consumption as the number of diabetic patients increases

·         Increase in R&D

·         Uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs.

What are the Type 1 Diabetes Market Barriers?

·         Entry of Biosimilars

·         High treatment and diagnosis Cost

·         Inadequate reimbursement policies